Clinical Trial: A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional




Official Title: A Multicenter Prospective Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

Brief Summary: The purpose of this study is to determine the efficacy and safety of crizotinib combined with CHOP chemotherapy for patients with ALK(+) Systemic Anaplastic Large Cell Lymphoma.